The case for systematic asset repurposing

Most asset repurposing efforts in life sciences are reactive. A program fails its primary indication. An unexpected signal emerges from a clinical dataset. A competitor's success in an adjacent indication prompts a reassessment. The repurposing effort that follows is real, but it is opportunistic — triggered by an event rather than driven by a systematic view of the asset's potential.

Organizations that treat repurposing as a systematic capability rather than a fallback consistently extract more value from their existing asset base. They maintain a structured view of their compounds' mechanisms, their competitive positions across indications, and the development costs and timelines associated with different repurposing paths. They make explicit decisions about which repurposing opportunities to pursue and which to deprioritize.

The economics of systematic repurposing are compelling. The cost of developing a compound for a second indication is substantially lower than the cost of developing a new compound. The probability of success is higher. The timeline is shorter. And the strategic optionality created by a successful repurposing program — in terms of revenue diversification, lifecycle extension, and portfolio balance — is significant.

The barrier is not analytical. Most organizations have the data they need to identify repurposing opportunities. The barrier is organizational: the governance processes, the resource allocation frameworks, and the incentive structures that determine whether repurposing opportunities get the attention they deserve.

Building a systematic repurposing capability requires treating it as a portfolio discipline — with dedicated resources, clear decision criteria, and governance processes that can evaluate repurposing opportunities alongside new development programs on a common framework.